FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
July 25, 2024 16:30 ET
|
Cellectis Inc.
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated1There is an urgent need to develop new therapies for...
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024 08:30 ET
|
FN Media Group LLC
PALM BEACH, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The fibromyalgia treatment market has witnessed positive growth trends over the past few years. There is higher...
Tiziana Life Sciences Granted FDA Fast Track Designation
July 24, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Kane Biotech Receives FDA Approval to Increase Dosage Allowance of its revyve™ Antimicrobial Wound Gel
July 23, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, July 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the US Food and Drug Administration (FDA)...
Radical™ Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery (SNIS) 21st Annual Meeting
July 22, 2024 17:00 ET
|
Radical Catheter Technologies
CAMPBELL, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Radical™ Catheter Technologies, a medical device company pioneering the next generation of endovascular access and delivery products, today...
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights
July 18, 2024 10:05 ET
|
Spherix Global Insights
EXTON, PA, July 18, 2024 (GLOBE NEWSWIRE) -- In February of this year, Takeda’s Eohilia (budesonide oral suspension) received FDA approval as the first and only oral therapy for eosinophilic...
Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
July 17, 2024 08:00 ET
|
Longeveron
Longeveron announces FDA has granted Fast Track designation to cellular therapy Lomecel-B(TM) for the treatment of mild Alzheimer’s Disease.
Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
July 16, 2024 09:02 ET
|
Clearmind Medicine Inc.
Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Kronos Advanced Technologies Inc. Warns Consumers to Use Only FDA-Cleared Air Purifiers at Home and Office
July 16, 2024 06:18 ET
|
Kronos Advanced Technologies Inc.
Los Angeles, CA , July 16, 2024 (GLOBE NEWSWIRE) -- Los Angeles, CA July 16, 2024 (GLOBE NEWSWIRE) -- KRONOS ADVANCED TECHNOLOGIES, INC. (OTC MARKETS: KNOS) ("KNOS" or the "Company"), an...
60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
July 09, 2024 06:31 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma wins IRB approval for tafenoquine study for treating persistent babesiosis in immunocompromised patients despite prior treatment.